Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Villa, Guillermo ^a   Hernández Pastor, Luis Javier ^a  

^a GLAXOSMITHKLINE   (Spain)

Author keywords

Budget impact analysis; Cost analysis; Kidney cancer; Markov models; Pazopanib; Renal cell carcinoma; Sunitinib

Indexed keywords

PAZOPANIB; SUNITINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADVANCED CANCER; ARTICLE; BUDGET; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; COST BENEFIT ANALYSIS; COST CONTROL; COST OF ILLNESS; DRUG COST; HEALTH CARE COST; KIDNEY CARCINOMA; MATHEMATICAL MODEL; SENSITIVITY ANALYSIS; SPAIN; CANCER STAGING; CARCINOMA, RENAL CELL; ECONOMICS; HUMAN; INCIDENCE; KIDNEY NEOPLASMS; ORGANIZATION; PATHOLOGY; PREVALENCE; PROBABILITY;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COST-BENEFIT ANALYSIS; DECISION MAKING, ORGANIZATIONAL; HEALTH CARE COSTS; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; MARKOV CHAINS; NEOPLASM STAGING; PREVALENCE; PYRIMIDINES; SPAIN; SULFONAMIDES;

EID: 84883195851     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-399     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. Cancer incidence in five continents (vol 9) 2008, Lyon, France: International Agency for Research on Cancer, World Health Organization.
3. Nelson EC, Evans CP, Lara PN. Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev 2007, 33:299-313. 10.1016/j.ctrv.2006.12.005, 17329029.
4. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000, 18:2972-2980.
5. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell. N Engl J Med 1998, 338:1272-1278. 10.1056/NEJM199804303381805, 9562581.
6. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134. 10.1056/NEJMoa060655, 17215530.
7. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007, 356:115-124. 10.1056/NEJMoa065044, 17215529.
8. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind, phase III trial. Lancet 2007, 370:2103-2111. 10.1016/S0140-6736(07)61904-7, 18156031.
9. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26:5422-5428. 10.1200/JCO.2008.16.9847, 2651074, 18936475.
10. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ. Temsirolimus, interferon alfa, or both for advanced renalcell carcinoma. N Engl J Med 2007, 356:2271-2281. 10.1056/NEJMoa066838, 17538086.
11. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456. 10.1016/S0140-6736(08)61039-9, 18653228.
12. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 2011, 16(suppl 2):14-22.
13. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068. 10.1200/JCO.2009.23.9764, 20100962.
14. National Comprehensive Cancer Network (NCCN) Guidelines, Kidney Cancer http://www.nccn.org.
15. Escudier B, Kataja V. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl):137-139.
16. Calvo E, Maroto P, del Muro XG, Climent MA, González-Larriba JL, Esteban E, López R, Paz-Ares L, Bellmunt J, Castellano D. Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. Cancer Metastasis Rev 2010, 29(Suppl 1):1-10.
17. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013, 369(8):722-31. 10.1056/NEJMoa1303989, 23964934.
18. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on Good Research Practices - Budget Impact Analysis. Value Health 2007, 10:336-347. 10.1111/j.1524-4733.2007.00187.x, 17888098.
19. Briggs A, Sculpher M. An introduction to Markov Modelling for economic evaluation. Pharmacoeconomics 1998, 13:397-409. 10.2165/00019053-199813040-00003, 10178664.
20. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 97:1663-1671. 10.1002/cncr.11234, 12655523.
21. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993, 13:322-338. 10.1177/0272989X9301300409, 8246705.
22. International Agency for Research on Cancer, GLOBOCAN 2008 http://globocan.iarc.fr.
23. National Statistics Institute http://www.ine.es.
24. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008, 34:193-205. 10.1016/j.ctrv.2007.12.001, 18313224.
25. Cohen HT, FJ MG. Renal-cell carcinoma. N Eng J Med 2005, 353:2477-2490.
26. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296. 10.1200/JCO.20.1.289, 11773181.
27. Database of the Spanish Council of Pharmacists http://www.portalfarma.com.
28. Isla D, González-Rojas N, Nieves D, Brosa M, Finnern HW. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clin Transl Oncol 2011, 13:460-471. 10.1007/s12094-011-0683-0, 21775273.
29. Ojeda B, de Sande LM, Casado A, Merino P, Casado MA. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Brit J Cancer 2003, 89:1002-1007. 10.1038/sj.bjc.6601228, 2376947, 12966416.
30. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, Purushotham AD, Naredi P, Eggermont A, Brennan MF, Steinberg ML, De Ridder M, McCloskey SA, Verellen D, Roberts T, Storme G, Hicks RJ, Ell PJ, Hirsch BR, Carbone DP, Schulman KA, et al. Delivering affordable cancer care in high income countries. Lancet Oncol 2011, 12:933-980. 10.1016/S1470-2045(11)70141-3, 21958503.
31. Ethgen O, Standaert B. Population versus cohort-based modelling approaches. Pharmacoeconomics 2012, 30:171-181. 10.2165/11593050-000000000-00000, 22283692.
32. Mar J, Sainz-Ezkerra M, Miranda-Serrano E. Calculation of prevalence with Markov models: budget impact analysis of thrombolysis for stroke. Med Decis Making 2008, 28:481-490. 10.1177/0272989X07312720, 18349439.
33. Mohamed AF, Hauber AB, Neary MP. Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics 2011, 29:977-988. 10.2165/11593370-000000000-00000, 21854079.